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Abstract. Urothelial bladder carcinoma (UBC) is heteroge-
neous in its pathology and clinical behaviour. Evaluation of 
prognostic and predictive biomarkers is necessary, in order to 
produce personalised treatment options. The present study used 
immunohistochemistry to evaluate UBC sections containing 
tumour and non-tumour areas from 76 patients, for the detec-
tion of p-mTOR, CD31 and D2-40 (blood and lymphatic 
vessels identification, respectively). Of the non-tumour and 
tumour sections, 36 and 20% were scored positive for p-mTOR 
expression, respectively. Immunoexpression was observed 
in umbrella cells from non-tumour urothelium, in all cell 
layers from non-muscle-invasive (NMI) tumours (including 
expression in superficial cells), and in spots of cells from 
muscle-invasive (MI) tumours. Positive expression decreased 
from non-tumour to tumour urothelium, and from pT1/pTis to 
pT3/pT4 tumours; however, the few pT3/pT4 positive cases had 
worse survival rates, with 5-year disease-free survival being 
significantly lower. Angiogenesis occurrence was impaired in 
pT3/pT4 tumours that did not express p-mTOR. In conclusion, 
p-mTOR expression in non-tumour umbrella cells is likely a 
reflection of their metabolic plasticity, and extension to the 
inner layers of the urothelium in NMI tumours is consistent 
with an enhanced malignant potential. The expression in cell 
spots in a few MI tumours and absence of expression in the 
remaining tumours is intriguing and requires further research. 
Additional studies regarding the up- and downstream effectors 
of the mTOR pathway should be conducted.
Introduction
Bladder cancer is the second most common urological 
malignancy and represents a significant epidemiological 
problem. There was an estimated 386,300 new cases and 
150,200 deaths in 2008, worldwide (1). Urothelial carcinoma 
is the most common histological subtype of bladder cancer 
in developed countries (2). The majority of patients present 
with non-muscle-invasive (NMI) tumours that, although lack 
aggressive histopathological features, frequently recur, which 
therefore demands for long-term follow-up and repeated inter-
vention. High-grade NMI lesions harbor an enhanced risk of 
progression to muscle-invasive (MI) disease. MI tumours have 
significant metastatic potential (3), for which radical cystec-
tomy (RC) with bilateral pelvic and iliac lymphadenectomy 
is the most common treatment (4,5). This surgical approach 
provides a cure for the majority of patients with organ-confined 
lesions (6). However, regional lymph node and visceral 
metastasis are common findings, advocating the association 
of neoadjuvant and adjuvant therapies. Cisplatin-containing 
combinations are standard treatment options of care for 
patients with urothelial bladder carcinoma (UBC), but hetero-
geneity in the response to the treatment and patient fragility 
significantly impairs the survival benefits (7). Up to 50% of 
patients with MI-UBC will eventually succumb to metastatic 
disease (6). 
Current investigations have started to research the molec-
ular pathogenesis of bladder tumours, in an attempt to identify 
biomarkers of aggressiveness, response to chemotherapy 
and potential therapeutic targets. The mammalian target of 
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rapamycin (mTOR) intracellular pathway represents a poten-
tial target. mTOR belongs to the phosphoinositide-3-kinase 
(PI3K)-related kinase family, and is centrally involved in 
the transduction of proliferative factors induced by the 
PI3K/Akt signalling pathway, to the level of mRNA and 
ribosomes (8-11). The mTOR gene encodes a protein product 
that functions as a component of two complexes, mTOR 
complex 1 (mTORC1) and mTORC2 (10). Through its interac-
tions with regulatory-associated protein of mTOR, contained 
in mTORC1, and rapamycin-insensitive companion of mTOR, 
contained in mTORC2, activated mTOR regulates protein 
translation, cell cycle progression, actin cytoskeleton organi-
zation, cell migration and survival (8-11). Furthermore, mTOR 
signalling can mediate angiogenesis and lymphangiogenesis 
by increasing vascular endothelial growth factor secretion. In 
addition, mTOR functions in the crosstalk between tumour and 
endothelial cells (12-14). Increased mTOR activity, as well as 
increased levels of phosphorylation of its downstream targets, 
eukaryotic translation initiation factor 4E binding protein 1 
and ribosomal protein S6 kinase, have been detected in a 
significant percentage of human tumours (15-22). Rapamycin 
(sirolimus) and rapamycin analogues (such as temsirolimus 
and everolimus), selectively inhibit the mTOR pathway, and 
have demonstrated potent antitumour effects both in vitro and 
in vivo (23-26). A number of these compounds have already 
obtained Food and Drug Administration approval for the 
treatment of human malignancies (27), and numerous clinical 
trials are ongoing (28,29), including trials for patients with 
UBC (30). There has been little research into the levels of 
mTOR activation in bladder tumour tissue, with inconsistencies 
in the existing results. Hansel et al (31) reported the expression 
of phosphorylated mTOR (p-mTOR) in 74% (90/121) of MI 
UBCs, and a significant association with increased patho-
logical stage and reduced disease-specific survival was noted. 
Conversely, Makhlin et al (32) found that p-mTOR expression 
was increased in malignant versus normal urothelium in only 
32% (65/203) of tumours, and no association with clinico-
pathological and outcome parameters was observed (32).
The present study aimed to evaluate the pattern of expres-
sion and the clinical and prognostic significance of p-mTOR, 
by immunohistochemistry, in 76 patients with high risk of 
UBC progression. Angiogenesis and lymphangiogenesis 
occurrence was also evaluated by immunohistochemistry, in 
order to correlate blood vessel density (BVD) and lymphatic 
vessel density (LVD) with p-mTOR expression.
Methods
Patient and tumour samples. The records from patients who 
were clinically diagnosed with a high risk of progressive 
UBC (high-grade NMI and MI tumours) and treated by RC 
and limited lymphadenectomy at the Portuguese Institute 
of Oncology (IPO) (Porto, Portugal), from January 1996 to 
December 2005, were retrospectively reviewed. Prior approval 
was obtained from the ethics committee of the Portuguese 
Institute of Oncology, and written informed consent was 
obtained from the patient/the patient's family. During 
this period, 223 RCs were performed. Exclusion criteria 
included the diagnosis of urothelial carcinomas with variant 
histology, squamous cell or adenocarcinomas, prior radiation, 
neoadjuvant or adjuvant chemotherapy treatments, insuf-
ficient follow-up time and/or tumour samples inadequate for 
further study (such as samples without adjacent non-tumour 
urothelium). A final cohort of 76 patients were eligible for the 
study. Each cystectomy specimen was examined following 
the guidelines of the College of American Pathologists (33). 
Two independent pathologists (A.L-F. and T.A.) reviewed 
haematoxylin-eosin-stained sections according to the stan-
dard histopathological examination methods, considering 
the American Joint Committee on Cancer (34) and the 
World Health Organization-WHO (WHO 1999 and WHO 
2004) (35,36) classification systems. Table I summarises the 
clinicopathological parameters.
The 61 patients with MI tumours (80%) had RC as their 
first treatment, while the 15 patients with NMI tumours 
(20%) had a previous therapeutic transurethral resection 
and BCG instillation. When disease recurrence occurred, or 
when multiple carcinoma in situ (CIS) lesions were observed 
in the surgical specimen, these patients were then treated 
by RC. The mean and median follow-up times were 35 and 
20 months (range, 1-132 months), respectively. Recurrence, 
disease-free survival (DFS) and overall survival (OS) rates 
were defined as the reappearance of UBC (loco-regional 
metastasis or distant metastasis) >3 months following RC, 
the time from RC until recurrence, and the time from RC 
until the patient succumbed to the cancer or the last clinical 
assessment, respectively.
Immunohistochemistry and evaluation of staining. 
Immunohistochemical staining to detect p-mTOR was 
performed on paraffin-embedded 4 µm UBC tissue 
sections following the horseradish peroxidase two-step 
peroxidase conjugated polymer method (EnVision™+ 
system; DakoCytomation, Glostrup, Denmark), according 
to the manufacturer's instructions. The monoclonal rabbit 
anti-human phospho-mTOR primary antibody (Ser2448; Cell 
Signalling Technology, Inc., Danvers, MA, USA) was used in 
a 1:500 dilution and incubated on the sections overnight at 4˚C. 
Samples processed by omitting the primary antibody were 
used as negative controls. A breast tumour with known immu-
noreactivity for p-mTOR was used as a positive control. Blood 
and lymphatic endothelial cells were immunohistochemically 
stained by monoclonal mouse anti-human CD31 and D2-40 
DakoCytomation antibodies (DakoCytomation), as previously 
described (37).
The immunostained sections were examined by light 
microscopy (Motic BA310 Series; Motic Spain, S.L.U., 
Barcelona, Spain) by two independent observers (A.L-F. 
and T.A.) who had no prior knowledge of the clinical 
status. Discordant cases were re-analysed together using 
a double-headed microscope (Olympus BX46; Olympus 
Corporation, Center Valley, PA, USA). The p-mTOR expres-
sion was semiquantitatively assessed at x200 magnification, 
considering the cytoplasmic staining of the tumour and 
adjacent, non-tumour urothelial cells. The following grading 
system was used: Negative (-), expression in <10% of cells; 
and positive (+) expression in ≥10% of cells. CD31 and D2-40 
immunohistochemical positive reactions were assessed as 
previously described, in order to quantify overall BVD and 
LVD (peritumoural and intratumoural), respectively (37).
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Statistical analysis. Data were analysed using SPSS 
software for Windows, version 20.0 (IBM, Portsmouth, 
UK). Associations between p-mTOR expression and the 
clinicopathological parameters were examined for statistical 
significance using Pearson's χ2 test or Fisher's exact test (when 
n<5). For BVD and LVD analysis, data are expressed as the 
median, and this value was used as a cut-off point for statis-
tical analysis. Five-year DFS and OS rates were evaluated 
using Kaplan-Meier curves, and differences were analysed by 
log-Rank or Breslow tests. P<0.05 was considered to indicate 
a statistically significant difference. 
Results
Prognostic significance of the clinicopathological param‑
eters. The 5-year DFS and OS rates were significantly lower 
in patients with tumours invading beyond the muscular layer, 
with grade III tumours, with occurrence of lymphovascular 
invasion or with the presence of regional metastases (Table II). 
High vascular density did not have an impact on the patholog-
ical outcome. However, high LVD was predominant in pT3/pT4 
(81%, 33/41, P=0.006), grade III (85%, 35/41, P=0.034) or MI 
(37/41, 90%, P=0.033) tumours (data not shown). 
Immunoexpression pattern of p‑mTOR. A total of 76 UBC 
samples with representative tumour and non-tumour (normal 
or hyperplasic urothelium) sections were evaluated for 
p-mTOR immunoexpression. Of these samples, 20% (15/76) 
were scored as positive. Regarding NMI papillary lesions, 
p-mTOR expression was observed to be frequently evenly 
distributed across the several layers of urothelial cells, with a 
more intense staining noted in the superficial layers (Fig. 1A). 
This superficial increase in p-mTOR expression was more 
evident in some NMI cases, (Fig. 1B). MI positive cases 
were rare, and p-mTOR was only expressed in a few spots of 
cells. In cases where non-tumour urothelium, with apparent 
normal histology (Fig. 1C) or hyperplasic samples (Fig. 1D) 
were scored as positive (36%, 27/76), p-mTOR expression was 
completely restricted to the superficial cell layers, predomi-
nantly to the umbrella cells. 
Clinical and prognostic significance of p‑mTOR immu‑
noexpression. The expression of p-mTOR decreased with 
increasing stage: 40% (6/15) of pT1 and pTis tumours were 
positively stained, while only 14.3% (7/49) of pT3/pT4 tumours 
expressed p-mTOR (P=0.087) (Table III). Similar correlations 
were found when considering the morphological type of lesion 
(P=0.075) (Table III). When comparing the positive tumour 
and non-tumour sections, concordance in the expression of 
p-mTOR was lost with enhanced tumour aggressiveness: 17 
pT3/pT4 cases presented positive normal-like mucosal regions 
adjacent to the tumour sections, but p-mTOR expression was 
only observed in 6 (35.3%) of these cases (P=0.005, data not 
shown). Occurrence of angiogenesis and lymphangiogenesis 
did not correlate with overall expression of p-mTOR. In the 
group of low blood vessel density count, 65% (26/40) of the 
cases did not express p-mTOR neither in the tumour nor 
non-tumour sections (P=0.003, data not shown). No signifi-
cant associations were observed regarding p-mTOR status and 
survival rates. However, when selecting the group of patients 
with pT3/pT4 tumours, those with negative expression had 
a median 5-year OS of 15.7 months (95% CI, 6.757-24.643), 
which was reduced to 3.5 months (95% CI, 1.000-8.514) if the 
tumours were p-mTOR positive, although the differences were 
not statistically significant (Fig. 2A). Accordingly, the 5-year 
DFS was reduced from 8.7 months (95% CI ,3.974-13.359) in 
the negative cases to 1.8 months (95% CI, 1.030-2.570) in the 
positive cases (P=0.004, Fig. 2B).
Discussion
The interplay between both mTOR complexes and the PI3K/Akt 
signalling pathway is support for the consistent upregulation of 
the mTOR network in numerous cancers. Activating mutations 
in the mTOR gene have been identified in a small number of 
malignancies, although these have not been clearly associ-
ated with tumour development (38). Conversely, upstream 
components of the mTOR pathway are frequently altered in 
human tumours (8,15), and UBC is not an exception, with 
reported mutations of phosphatidylinositol-4,5-bisphosphate 
3-kinase, catalytic subunit alpha, AKT1 and tuberous sclerosis 
Table I. Clinicopathological parameters.
Parameter n
Gender
  Male 63
  Female 13
Age, years
  Median 71
  Range 41-83
Tumour stage
  pT1 and pTis 15
  pT2 12
  pT3 and pT4 49
Grade
  II 19
  III 57
Morphological type of lesion
  Non-muscle invasive papillary 11
  In situ   4
  Muscle-invasive 61
Lymphovascular invasion
  Yes 37
  No 39
Loco-regional dissemination
  Yes 22
  No 54
Recurrence
  Yes 57
  No 19
Clinical outcome
  Succumbed to bladder cancer 53
  Alive, lost to follow-up, or dead due to other causes 23
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Figure 1. Immunohistochemical positive reactions for p-mTOR, showing different expression patterns in urothelial cells. Non-muscle invasive papillary tumours 
expressing cytoplasmic p-mTOR in (A) near homogeneous (magnification, x200) and (B) and heterogeneous (magnification, x100) patterns. The luminal and inter-
mediate cell layers were more intensely stained than the basal cell layer. (C) Normal (magnification, x400) and (D) hyperplasic (magnification, x200) urothelium 
exhibiting cytoplasmic p-mTOR immunoexpression restricted to the superficial layers. p-mTOR, phosphorylated mammalian target of rapamycin.
Table II. Correlation between 5-year disease-free survival and overall survival rates, and clinicopathological variables.
Parameter n 5-year DFS rate (%) P-valuea 5-year OS rate (%) P-valuea
Gender
  Male 63 22.0 0.608 31.3 0.780
  Female 13 34.6  34.2 
Age, years
  ≤71 40 25.6 0.288 33.5 0.317
  >71 36 22.4  30.3 
Stage
  pT1 and pTis 15 36.1 0.011 46.5 0.005
  pT2 12 27.8  45.8 
  pT3 and pT4 49 20.4  23.7 
Grade
  II 19 45.5 0.007 61.2 0.001
  III 57 17.2  22.3 
Morphological type of lesion
  Non-muscle invasive papillary 11 30.7 0.059 48.5 0.048
  In situ   4 50.0  50.0 
  Muscle-invasive 61 21.5  28.1 
Lymphovascular invasion
  Negative 39 30.2 0.040 42.9 0.004
  Positive 37 18.9  21.0 
Loco-regional metastasis
  Negative 54 28.8 0.043 41.1 0.001
  Positive 22 13.6  10.0 
aObtained using the log-rank or Breslow test. DFS, disease-free survival; OS, overall survival.
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Table III. Correlation between p-mTOR expression status in tumour sections and clinicopathological variables.
  p-mTOR expression (%)
  ------------------------------------------------------------------
Parameter n Negative Positive P-valuea
Gender
  Male 63 48 (76.2) 15 (23.8) 0.060
  Female 13 13 (100) 0 (0.0) 
Age, years
  ≤71 40 31 (77.5)   9 (22.5) 0.534
  >71 36 30 (83.3)   6 (16.7) 
Stage
  pT1 and pTis 15   9 (60.0)   6 (40.0) 0.087
  pT2 12 10 (83.3)   2 (16.7) 
  pT3 and pT4 49 42 (85.7)    7 (14.3) 
Grade
  II 19 14 (73.7)   5 (26.3) 0.507
  III 57 47 (82.5) 10 (17.5) 
Morphological type of lesion
  Non-muscle invasive papillary 11   7 (63.6)   4 (36.4) 0.075
  In situ   4   2 (50.0)   2 (50.0) 
  Muscle-invasive 61 52 (85.2)   9 (14.8) 
Lymphovascular invasion
  Negative 39 29 (74.4) 10 (25.6) 0.252
  Positive 37 32 (86.5)   5 (13.5) 
Loco-regional metastasis
  Negative 54 42 (77.8) 12 (22.2) 0.532
  Positive 22 19 (86.4)   3 (13.6) 
Median BVD (CD31 stain)
  <17.6 40 33 (82.5)   7 (17.5) 0.774
  ≥17.6 36 28 (77.8)   8 (22.2) 
Median LVD (D2-40 stain)
  <8.8 35 26 (74.3)   9 (25.7) 0.259
  ≥8.8 41 35 (85.4)   6 (14.6) 
aObtained using the χ2 or Fisher exact test. BVD, blood vessel density; LVD, lymphatic vessels density.
Figure 2. Kaplan-Meier survival curves demonstrating (A) 5-year overall survival (P>0.05) and (B) 5-year disease-free survival (P=0.004) based on p-mTOR 
immunoexpression status in pT3/pT4 urothelial bladder. P-value presents the differences between the p-mTOR-negative and -positive cases.
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protein 1, hamartin, and loss of heterozygosity, homozygous 
deletion and inactivating mutations of phosphatase and tensin 
homologue deleted on chromosome 10 (39,40). These observa-
tions strongly suggest that mTOR signalling may be activated 
in bladder tumours. In accordance with this hypothesis, 
mTOR inhibition through rapamycin or rapamycin analogues 
has been shown to reduce proliferation in in vitro and in 
vivo UBC models, with corresponding diminished levels of 
p-S6 (31,32,41). Notably, treatment with mTOR inhibitors has 
been observed to enhance the therapeutic efficacy of cisplatin 
and gemcitabine in bladder cancer cell lines (32,42,43), and 
impair tumour progression when administered intravesically 
in a bladder cancer mouse model (44). In a phase II study 
of everolimus treatment in patients with locally advanced or 
metastatic UBC, clinical activity was demonstrated, and the 
profile of plasma angiogenesis-related proteins suggested 
that everolimus exhibits antiangiogenic properties that have 
a significant function in disease control (45). Despite these 
promising results, little is known regarding the prevalence 
and clinical relevance of p-mTOR expression in UBC tissue. 
A better understanding on this subject may be important to 
appropriately identify patients with UBC that can achieve 
benefits from molecularly targeted therapies. 
Phosphorylation of mTOR at Ser2448 is often used as 
an indicator of mTOR activity (15,46). In three studies using 
the same p-mTOR antibody (with slight differences in the 
protocols and quantification methods), the percentage of 
bladder tumour samples with activated mTOR ranged from 
32 to 88% (31,32,47). While some authors identified p-mTOR 
upregulation as an important prognostic factor (31,48), others 
have found an overall downregulation of the mTOR pathway 
in UBC (49). Comprehensive immunohistochemical and 
molecular approaches, encompassing several mTOR upstream 
and downstream factors, are better suited for investigating 
the potential impact of this pathway in patients with UBC; 
however, inconsistent results have been described. Reports 
on p-Akt (47,48) and p-S6K/p-S6 (31,47,48) upregulation 
in tumour versus non-tumour urothelium contradict those 
reporting p-Akt (49) and p-S6 (49,50) downregulation. A 
few studies have demonstrated positive associations between 
mTOR pathway activation and the clinicopathological param-
eters of bladder tumours (48,50), while others have failed to 
do so (32) or have reported inverse associations (49). It can be 
argued that heterogeneity among patient selection criteria, and 
relative proportions of differently staged and graded tumours, 
immuno histochemical protocols or evaluation of staining 
methods may significantly contribute to the conflicting results 
that have been described. However, the unique biological 
features that define bladder tumourigenesis and tumour 
progression, together with the intrinsic complexity of the 
PI3K/Akt/mTOR pathway, are likely the predominant factors 
in this disease.
In the present study, only p-mTOR expression was evalu-
ated in a cohort of 76 UBC tumours, which although may 
constitute a limitation, was analysed together with markers of 
blood and lymphatic endothelium. Only 20% of the tumour 
samples were scored positive for p-mTOR expression; the 
adjacent non-tumour urothelium (apparently normal or hyper-
plasic) was immuno stained in 36% of the tissue sections, 
although only the superficial layers, including umbrella cells, 
were stained. In the malignant urothelium of NMI lesions, 
an evenly distributed pattern of expression was frequently 
observed, but the stronger intensity of staining in the super-
ficial layers was maintained. p-mTOR expression decreased 
with increasing stage, and MI tumours were predominantly 
negative. In cases of positive MI tumours, only small clus-
ters of cells were stained. Interestingly, normal-like mucosa 
of MI lesions preserved p-mTOR expression in a significant 
proportion of cases that had lost it in the tumour sections. 
No significant association was found between p-mTOR posi-
tivity and neovascularization. When tumour and non-tumour 
sections were simultaneously negative, the occurrence of 
angiogenesis was observed to be compromised. In the group 
of pT3/pT4 tumours, p-mTOR expression was associated with 
a worse survival rate, although the differences were only 
significant for 5-year DFS.
The pattern of p-mTOR immunoexpression that was 
observed in the UBC series of the present study has been 
similarly described in previous studies (32,48). It may be 
speculated that the restriction of p-mTOR expression to the 
superficial layers of the normal-like urothelium reflects the 
biological plasticity inherent to the epithelial cells, namely 
the umbrella cells. These cells exhibit unique structural and 
biochemical features that enable them to form an effective 
permeable barrier while supporting mechanical deforma-
tion due to bladder filling (51,52). It is likely that constitutive 
expression of mTOR is necessary for normal metabolic activi-
ties. It has been previously described that mTORC1, besides 
being a master regulator of cell growth and proliferation in 
non-tumour and tumour conditions, additionally controls 
specific aspects of cellular metabolism through the induction 
of metabolic gene expression (53-55). Consistent with the 
results of the present study, NMI tumours may extend and 
upregulate mTOR expression up to the basal urothelial layer, 
which is concordant with an enhanced malignant potential 
that will guide growth and progression of the primary tumour. 
Fahmy et al (56) have recently reported that activation of the 
mTOR pathway may be used as a predictor of recurrence 
among patients with high-risk NMI (56). It was shown by 
Pinto-Leite et al (43) that the effect of everolimus in bladder 
cancer cell lines, alone or in combination with gemcitabine 
treatment, produced a significant antiproliferative effect for 
everolimus in an NMI cell line (5637), while an MI cell line 
(T24) demonstrated marked resistance. These results, together 
with the results from the present study, suggest that interfering 
with the mTOR pathway may represent an appealing approach 
for therapeutic intervention in patients with NMI tumours.
In the present group of MI tumours, two p-mTOR pheno-
types were observed. Firstly, positive pT3/pT4 tumours were 
associated with a worse prognosis, which is in accordance with 
previous data that have reported upregulation of the mTOR 
pathway as an important prognostic factor (31,48). Secondly, 
p-mTOR positivity was rare and restricted to cell spots. In 
the majority of MI tumour sections, immuno expression was 
lost in a de novo fashion, as supported by the maintenance of 
p-mTOR expression in the normal-like adjacent mucosa. It is 
hypothesised that unknown biological determinants are func-
tioning in the promotion of this unique malignant scenario. 
Schultz et al (49) reported the apparent downregulation of the 
mTOR pathway, as demonstrated by the low expression levels 
ONCOLOGY LETTERS  8:  1447-1454,  2014 1453
of p-Akt and p-S6 in invasive UBC, as compared with benign 
urothelium. It was hypothesised that the downregulation of 
p-S6 in MI-UBC may be related to the hypoxia-inducible 
factor-activating hypoxia-resistant microenvironment. 
Müller et al (57) demonstrated that when comparing between 
normal and prostate tumour tissues, p-mTOR expression was 
reduced in the tumour, correlating with adverse clinicopatho-
logical features. These results, together with the data of the 
present study, may reflect the occurrence of alternative mTOR 
signalling mechanisms that underlie the classical PI3K/Akt 
activation pathway. Additional studies with a larger and more 
comprehensive UBC series and panels of mTOR upstream and 
downstream effectors, together with reproducible immunohis-
tochemical and molecular approaches and in vivo and in vitro 
bladder tumour models, are required to clarify the mechanism 
of the mTOR pathway in human UBC, in order to expedite the 
research on novel therapeutic approaches.
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